Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00026728 · ClinicalTrials.gov registry record

Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
20,169
Enrollment target

NCT00026728: Completed study, sponsored by National Cancer Institute (NCI).

NCT00026728 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 20,169 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00026728 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
20,169 participants
Enrollment target

Study Summary

This study will investigate patterns of Kaposi's sarcoma herpes virus (KSHV) in the United States and its potential impact on the U.S. population. KSHV is a newly discovered virus that is strongly associated with Kaposi's sarcoma and primary effusion lymphoma. The high prevalence of KS and KSHV among HIV-infected homosexual men suggests sexual contact as a primary mode of transmission. Reports of non-sexual transmission in parts of Africa and the Mediterranean where Kaposi's sarcoma is endemic, and the identification of viral DNA in saliva and other bodily fluids, however, indicate the virus is also transmitted non-sexually. This study will: * Compare the prevalence of KSHV among different demographic groups in the United States * Examine the association between KSHV and high risk behaviors such as drug use (marijuana and cocaine), sexual behavior (age at first sexual intercourse and number of sexual partners), and medical risk factors (herpes simplex virus II, hepatitis B and hepatitis C) * Estimate the prevalence of KSHV in the United States. Data and blood samples for the study will be taken from the NHANES III survey. NHANES is a program of periodic surveys conducted by the Centers for Disease Control and Prevention's National Center for Health Statistics. The survey is designed to provide national estimates of health status for the United States non-institutionalized civilian population by means of household interviews, standardized physical examinations, and blood sample collection and testing. NHANES III-the seventh in a series of national examination studies-was conducted from 1988 to 1994. This study will use the HANES data to identify risks associated with a KSHV-positive blood test in the survey population. The study plans to include all 19,754 participants (67% of the 29,314 participants originally examined) for whom blood samples were collected and remain available.

Trial Details

FieldValue
Enrollment Target 20,169 participants
Start Date 2001-02
Est. Completion 2005-12
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00026728 record still lists

NCT00026728 is an observational study that tracks outcomes without assigning an intervention. Its 20,169 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT00026728 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00026728 about?

NCT00026728 is a clinical study titled "Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States". This study will investigate patterns of Kaposi's sarcoma herpes virus (KSHV) in the United States and its potential impact on the U.S. population. KSHV is a newly discovered virus that is strongly associated with Kaposi's sarcoma and primary effusion lymphoma. The high prevalence of KS and KSHV amon...

What is the current status of trial NCT00026728?

This trial is currently completed. The enrollment target is 20,169 participants. The study started on 2001-02. Estimated completion is 2005-12.

Who is sponsoring clinical trial NCT00026728?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00271180 · 20,000 participants

    Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

  • NCT00830557 · 20,000 participants

    Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders

  • NCT00900471 · 20,000 participants

    Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors

  • NCT02735707 · 20,000 participants · Phase 3

    Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00026728, the US trial registry maintained by the National Library of Medicine. NCT00026728 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.